NRx Pharmaceuticals closes $2.9M registered direct offering of common stock and warrants

NRX Pharmaceuticals, Inc.

Gross proceeds of ~$2.9M from sale of 3,766,666 shares and 3,766,666 warrants at $0.75 per unit.
All investors are existing holders; shares restricted from transfer for 6 months.
Warrants exercisable at $0.75 starting 6 months after issuance, expiring in 5 years.
Proceeds to fund working capital and initiate national treatment protocol for NRX-101 for bipolar depression with suicidal risk.
Offering closed on March 9, 2023 under existing effective S-3 registration statement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NRX Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the purchasers listed on the signature page thereto (the "Investors") valued at $0.75 per share (effective 2023-03-08).

Action: entry
Agreement: equity purchase
Counterparty: the purchasers listed on the signature page thereto (the "Investors")
Value: $0.75 per share
Effective: 2023-03-08

Exact text from the filing

On March 8, 2023, NRx Pharmaceuticals, Inc. (the "Company," "us" or "we") entered into a securities purchase agreement (the "Securities Purchase Agreement") with the purchasers listed on the signature page thereto (the "Investors"), providing for the issuance and sale of 3,766,666 shares of the Company's common stock

View on SEC.gov

Browse all material agreements →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-030356

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.